Neoarsphenamine

WikiDoc Resources for Neoarsphenamine
Articles
Most recent articles on Neoarsphenamine Most cited articles on Neoarsphenamine Review articles on Neoarsphenamine Articles on Neoarsphenamine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Neoarsphenamine Images of Neoarsphenamine Photos of Neoarsphenamine Podcasts & MP3s on Neoarsphenamine Videos on Neoarsphenamine
Evidence Based Medicine
Cochrane Collaboration on Neoarsphenamine Bandolier on Neoarsphenamine TRIP on Neoarsphenamine
Clinical Trials
Ongoing Trials on Neoarsphenamine at Clinical Trials.gov Trial results on Neoarsphenamine Clinical Trials on Neoarsphenamine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Neoarsphenamine NICE Guidance on Neoarsphenamine NHS PRODIGY Guidance FDA on Neoarsphenamine CDC on Neoarsphenamine
Books
Books on Neoarsphenamine
News
Neoarsphenamine in the news Be alerted to news on Neoarsphenamine News trends on Neoarsphenamine
Commentary
Blogs on Neoarsphenamine
Definitions
Definitions of Neoarsphenamine
Patient Resources / Community
Patient resources on Neoarsphenamine Discussion groups on Neoarsphenamine Patient Handouts on Neoarsphenamine Directions to Hospitals Treating Neoarsphenamine Risk calculators and risk factors for Neoarsphenamine
Healthcare Provider Resources
Symptoms of Neoarsphenamine Causes & Risk Factors for Neoarsphenamine Diagnostic studies for Neoarsphenamine Treatment of Neoarsphenamine
Continuing Medical Education (CME)
CME Programs on Neoarsphenamine
International
Neoarsphenamine en Espanol Neoarsphenamine en Francais
Business
Neoarsphenamine in the Marketplace Patents on Neoarsphenamine
Experimental / Informatics
List of terms related to Neoarsphenamine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Template:Chembox E number

Neoarsphenamine

Names
Other names Sodium 3,3'-diamino-4,4'-dihydroxyarsenobenzene -N-formaldehydesulfoxylate neoarsphenamine
Identifiers
CAS Number	457-60-3
3D model (JSmol)	Interactive image
ECHA InfoCard
PubChem CID	9980
SMILES C1=CC(=C(C=C1[As]=[As]C2=CC (=C(C=C2)O)NCS(=O)[O-])N)O.[Na+]
Properties
Chemical formula	C13H13As2N2NaO4S
Molar mass	466.152
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Neosalvarsan is a synthetic chemotherapeutic that is an organoarsenic compound. It became available in 1912 and superseded the more toxic and less water-soluble salvarsan as an effective treatment for syphilis. Because both of these arsenicals carried considerable risk of side-effects, they were replaced for this indication by penicillin in the 1940s.

Both salvarsan and neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. This scheme is the basis for most modern pharmaceutical research. Both salvarsan and neosalvarsan are prodrugs, that is to say that they are metabolised to the active drug in the body.

Structure

The structure of Salvarsan, and presumably this derivative, was once believed to feature an As=As bond as shown in the figure.. In 2005, Salvarsan was shown to be a mixture of the cyclic trimer and a pentamer. The revised structure features As-As single bonds, not double bonds.